🇺🇸 FDA

Company profile · Sponsor

Aptevo

Aptevo Therapeutics

APVO · NYSE pharma SEATTLE, WA, USA
Pipeline
9
Drugs
0
Patents
8

Quick answer

Aptevo (APVO) is a pharma company. headquartered in SEATTLE, WA, USA. listed on NYSE. NovaPharmaNews links 9 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker APVO
Exchange NYSE
Company type pharma
Headquarters SEATTLE, WA, USA
SEC CIK 0001671584

Pipeline (9)

Search pipeline →

  1. ALG.APV-527

    Aptevo

    Solid Tumor

    phase 2 small molecule active

    1 trial

  2. TRU-016 and bendamustine

    Aptevo

    Chronic Lymphocytic Leukemia (CLL)

    phase 2 small molecule completed

    1 trial

  3. 20 mg/kg TRU-016 + Rituximab

    Aptevo

    Chronic Lymphocytic Leukemia

    phase 1 mab terminated

    1 trial

  4. APVO210

    Aptevo

    Psoriasis

    phase 1 mab terminated

    1 trial

  5. APVO436

    Aptevo

    AML

    phase 1 mab active

    2 trials

  6. APVO436

    Aptevo

    Acute Myeloid Leukemia (AML)

    phase 1 small molecule active

    1 trial

  7. ES414

    Aptevo

    Prostate Cancer

    phase 1 mab completed

    1 trial

  8. TRU-016

    Aptevo

    B-cell Small Lymphocytic Lymphoma Recurrent

    phase 1 small molecule completed

    1 trial

  9. TRU-016 (anti-CD37 protein therapeutic)

    Aptevo

    Chronic Lymphocytic Leukemia (CLL)

    phase 1 small molecule completed

    1 trial

Patents (8)

Search patents →

  1. US 11939392

    CD123 binding proteins and related compositions and methods

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11725060

    Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods

    Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11352426

    CD3 binding polypeptides

    Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11312786

    Oncofetal antigen binding proteins and related compositions and methods

    Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11242400

    CD123 binding proteins and related compositions and methods

    Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10676533

    Methods of treatment of CD123 overexpressing disorders

    Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10307481

    CD37 immunotherapeutics and uses thereof

    Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10239949

    Oncofetal antigen binding proteins and related compositions and methods

    Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Aptevo?

Aptevo (APVO) is a pharma company. headquartered in SEATTLE, WA, USA. listed on NYSE. NovaPharmaNews links 9 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Aptevo sponsor?

We track 9 ClinicalTrials.gov-linked programs for Aptevo, including ALG.APV-527 and 8 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Aptevo company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.